Electroconductive GelMA-CNT Microneedle for Deep Tissue Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional microneedle technologies face challenges in delivering therapeutic agents effectively to deep subcutaneous tissues, lacking responsiveness to stimuli and failing to address deep tissue infections, with existing solutions often causing adverse effects and limited drug penetration.
Innovation Solution
An electroconductive microneedle patch composed of biocompatible GelMA and CNTs, activated by an external electrical field, enables on-demand drug release and penetration into deep tissues, disrupting microbial biofilms and stimulating neuro-immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If conventional microneedles are used for drug delivery, then minimally invasive access is achieved, but deep tissue penetration and drug delivery effectiveness are insufficient
Solution Approach 1:
The microneedle employs a composite structure combining conductive polymer matrix with carbon nanotube reinforcements. This composite material provides both mechanical strength for deep tissue penetration and electrical conductivity for stimulated drug release, resolving the contradiction between minimally invasive access and deep tissue delivery effectiveness
Solution Approach 2:
The patent replaces passive mechanical diffusion-based drug delivery with an electrically-stimulated active delivery system. External electrical stimulation activates the conductive microneedle to rapidly release drugs into deep tissues through electro-osmotic flow and electroporation mechanisms, significantly enhancing deep tissue penetration beyond what conventional passive microneedles can achieve
2Object-affected harmful factors
If biodegradable polymer-based microneedles are used, then biocompatibility is achieved, but responsiveness to stimuli and controlled drug delivery are lacking
Solution Approach 1:
The conductive polymer matrix combined with carbon nanotubes creates a material that maintains biocompatibility while gaining electrical conductivity and stimulus responsiveness. The carbon nanotubes provide conductive pathways that enable electrical stimulation responses without compromising the biocompatible polymer matrix, thus achieving both biocompatibility and stimulus responsiveness
Solution Approach 2:
The microneedle transitions from a static passive delivery system to a dynamic responsive system. Upon electrical stimulation, the conductive polymer matrix undergoes electro-osmotic flow and electroporation effects, dynamically adjusting its properties to enable controlled, on-demand drug release. This dynamic response capability allows the system to adapt to external stimuli and control drug delivery timing and rate
3Reliability
If high doses of potent drugs are administered orally or systemically, then therapeutic effectiveness is achieved, but severe adverse effects occur
Solution Approach 1:
The microneedle delivers drugs locally and directly to the site of infection or target tissue, concentrating the therapeutic agent precisely where needed. This localized delivery approach achieves effective therapeutic concentrations at the target site without the systemic distribution that causes adverse effects, thereby improving therapeutic effectiveness while reducing harmful side effects
Solution Approach 2:
The patent replaces systemic oral or intravenous drug administration with a localized minimally invasive delivery system. The electrically-stimulated conductive microneedle provides controlled, on-demand release of therapeutic agents directly into deep tissues, eliminating the need for high systemic doses and their associated adverse effects while maintaining therapeutic effectiveness at the target site
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The patch achieves precise, painless delivery of therapeutic agents to deep tissues, enhancing drug utilization rates, reducing side effects, and promoting immune responses, effectively eradicating deep infections with minimal discomfort.
Implementation Method 1
The combination of MN technology with the direct electrical stimulation creates an electrical field-based electro-osmotic movement which enable the robust release of therapeutic molecule drugs
Implementation Method 2
the electrical field activates the electroconductive microneedle patch, enabling on-demand release of therapeutic agents through iontophoresis and electroporation mechanisms
Implementation Method 3
The combination of MN technology with the direct electrical stimulation creates an electrical field-based electro-osmotic movement which enable the robust release of therapeutic molecule drugs into deep tissue layers
Implementation Method 4
An electroconductive microneedle patch composed of biocompatible GelMA and CNTs, activated by an external electrical field
Data Source
AI summary
The present invention relates to a novel microneedle platform for minimally invasive delivery of therapeutic agents and the modulation of the neuro-immune axis in deep tissue. The present invention also adopts an innovative approach for minimally invasive and precisely controllable treatment of deep cutaneous diseases, conditions, and disorders using said electroconductive MN patch, which has the potential to benefit millions of patients worldwide.